The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.

Zohreh SafipourRogier van der Zanden Joop P W van den Bergh Paddy Koen Camiel JanssenPeter VestergaardFrank de Vries Annemariek H M Driessen

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)

This study showed that oral GC use in patients with MG was not associated with increased risk of MOF in our case-control study and pooled analysis. Osteoporosis prevention in MG patients based on clinical guidelines remains advisable.

Keyphrases

myasthenia gravis
end stage renal disease
bone mineral density
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
body composition
high resolution
hip fracture
tandem mass spectrometry